Compare Credo Technology Group Holding Ltd (CRDO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs GeneDx Holdings Corp — how do they compare? Credo Technology Group Holding Ltd trades at $273.29 (market cap $46.19B), while GeneDx Holdings Corp trades at $82 (market cap $2.44B). The key difference: Credo Technology Group Holding Ltd is far larger — about 18.9× GeneDx Holdings Corp's market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| CRDO | WGS | |
|---|---|---|
Market Cap | $46.19B | $2.44B |
Sector | Technology | Technology |
52-Week High | $302.52 | $167.51 |
52-Week Low | $87.81 | $34.51 |
Enterprise Value | $44.77B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $257.10, up 7.15% today, with strong bullish momentum supported by technical indicators and positive analyst sentiment. The stock shows robust fundamentals with 157% revenue growth in Q4 2025 and consistent earnings beats. Recent news highlights Credo's strategic positioning in AI infrastructure, including contributions to the Open Compute Project and institutional investment increases.
Outlook remains positive with 86.7% analyst buy ratings and a $285.42 consensus price target, though premium valuations (P/E 98.7) and recent insider selling warrant caution. Key risks include customer concentration and execution challenges in the competitive AI hardware space.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
